Friday, October 30, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Meta Platforms: From Heavy AI CapEx to 2026 ROI?

View original at finance.yahoo.com
Meta Platforms: From Heavy AI CapEx to 2026 ROI? This article first appeared on GuruFocus. This past year, Meta Platforms (NASDAQ:META) invested heavily in AI infrastructure, shaking Wall Street's near-term confidence…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Time spent on Facebook rose 5% in Q3 2025

    80% confidence

  • Reels is running at a roughly $50 billion annualized revenue rate

    80% confidence

  • Threads usage jumped 10% in Q3 2025

    80% confidence

  • Instagram video consumption is up more than 30% year-over-year

    80% confidence

  • Lead-gen campaigns using Advantage+ show a 14% lower cost per lead than traditional campaigns

    80% confidence

  • Advantage+ is handling over $60 billion in annual ad spend

    80% confidence

  • Average price per ad rose 10% year-over-year in Q3 2025, credited to AI

    80% confidence

  • Meta has spent over $40 billion on R&D to date, with a significant portion allocated to AI/ML

    80% confidence

  • 2026 expenses will likely grow at a significantly faster rate than in 2025, largely due to infrastructure and personnel costs as new data center capacity comes online

    80% confidence

  • 2025 capital expenditures will exceed $70 billion, approximately 70% higher than in 2024

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
Meta Platforms: From Heavy AI CapEx to 2026 ROI? — Source | Via News | Finance Via News